Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis

被引：0

作者：

Bresnihan, B ^{[1
]}

机构：

[1] St Vincents Univ Hosp, Dublin 4, Ireland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2002年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Interleukin 1 (IL1) plays a central part in the pathophysiology of rheumatoid arthritis (RA).(1 2) The IL1 gene family includes IL1alpha, IL1beta, and IL1 receptor antagonist (IL1Ra). IL1alpha and IL1beta are both agonist molecules. There are two distinct IL1 receptors, designated type I (IL1RI) and type II (IL1RII). IL1 binding to IL1RI results in signal transduction and cell activation. IL1Ra is the third member of the IL1 gene family. The agonistic effects of IL1 arc partially blocked by the interaction between IL1Ra and IL1RI. When IL1Ra binds to IL1RI, it blocks the binding of IL1alpha and IL1beta and inhibits signal transduction. Recombinant human IL1Ra, anakinra, has been approved for the treatment of patients with rheumatoid arthritis (RA).

引用

页码：74 / 77

页数：4

共 11 条

[1]

Bresnihan B, 2001, ARTHRITIS RHEUM, V44, pS77

[2]

Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO

[3]

2-2

[4] Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [J].

Cohen, S ;

Hurd, E ;

Cush, J ;

Schiff, M ;

Weinblatt, ME ;

Moreland, LW ;

Kremer, J ;

Bear, MB ;

Rich, WJ ;

McCabe, D .

ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :614-624

[5] Anti-interleukin-1 therapy in rheumatic diseases [J].

Dayer, JM ;

Feige, U ;

Edwards, CK ;

Burger, D .

CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (03) :170-176

[6] The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1 [J].

Dinarello, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10) :732-734

[7]

EMERY P, 2001, ANN RHEUM DIS, V60, pS162

[8] THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].

FELSON, DT ;

ANDERSON, JJ ;

BOERS, M ;

BOMBARDIER, C ;

CHERNOFF, M ;

FRIED, B ;

FURST, D ;

GOLDSMITH, C ;

KIESZAK, S ;

LIGHTFOOT, R ;

PAULUS, H ;

TUGWELL, P ;

WEINBLATT, M ;

WIDMARK, R ;

WILLIAMS, HJ ;

WOLFE, F .

ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740

[9] MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS [J].

FRIES, JF ;

SPITZ, P ;

KRAINES, RG ;

HOLMAN, HR .

ARTHRITIS AND RHEUMATISM, 1980, 23 (02) :137-145

[10]

Jiang YB, 2000, ARTHRITIS RHEUM, V43, P1001, DOI 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO

← 1 2 →